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What is already known? 
 Clonidine is in widespread use as a sedative in paediatric critical care despite a limited 
evidence base for efficacy 
 A variety of dosage regimens have been employed in previous studies and in clinical practice 
What does this article add? 
 Clonidine dosage regimens used in practice and research studies are likely suboptimal  
 Clonidine titrated infusions with a loading dose of 2 µg/kg followed by a continuous infusion of 
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up to 2 µg/kg/hr are recommended in haemodynamically stable PICU patients to achieve 
adequate sedation. Doses should be halved in neonates.  
 
Summary  
Background: Clonidine is in widespread off-label use as a sedative in mechanically ventilated 
children, despite limited evidence of efficacy. A variety of dosage regimens have been utilised in 
clinical practice and in research studies. Within these studies, clonidine has inconsistently shown 
useful sedation properties. One of the reasons attributed to the inconsistent signs of efficacy is 
suboptimal clonidine dosing. 
Aim: This study aims to propose a target plasma concentration and simulate clonidine 
pharmacokinetics (PK) in a cohort of mechanically ventilated children to evaluate the adequacy of 
clonidine dosage regimens used in clinical practice and research studies. 
Method: A literature search was undertaken to identify a clonidine PKPD model, from which a target 
concentration for sedation was defined. Using a previously published PK model the projected plasma 
concentrations of 692 mechanically ventilated children (demographics taken from a recent study) 
were generated.  Doses from recently published clinical studies were investigated. Adequacy of each 
regimen to attain therapeutic clonidine plasma concentrations was assessed.  
Results: A target plasma concentration of above 2 µg/L was proposed. Nine dosage regimens (four 
intravenous boluses, four intravenous infusions and one nasogastric route boluses) were evaluated 
ranging from 1µg/kg 8 hourly intravenous boluses to a regimen up to 3µg/kg/hr continuous 
intravenous infusion. Regimens with a loading dose of 2µg/kg followed by variable continuous infusion 
of up to 2µg/kg/hr titrated according to sedation score appear most suitable. 
Conclusions: The variety of dosage regimens in previous studies of clonidine along with difficulties in 
the conduct of interventional studies may have contributed to the lack of efficacy data to support its 
use. Simulations of clonidine plasma concentrations based on known population pharmacokinetic 
parameters suggest a loading dose followed by higher than current practice maintenance dose 
infusion is required to achieve adequate steady-state concentrations early in treatment. Further PKPD 
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studies will aid in the determination of the optimal clonidine dosage regimen. 
 
Keywords: Clonidine, pharmacokinetics, conscious sedation, child, computer simulation, adrenergic 
alpha-agonists 
Background: 
The α2 agonists have been of intense interest in the paediatric critical care literature as 
sedative agents.
1,2
 An alternative mechanism of action to opioids and benzodiazepines makes them 
attractive to clinicians. Some of this interest has been extrapolated from the robust evidence base to 
support the use of the short-acting α2 agonist dexmedetomidine in adults.
3,4
 The older α2 agonist 
clonidine has been in off-label use in the Paediatric Intensive Care Unit (PICU) for decades.
5
 Less is 
known about clonidine’s efficacy despite it being an older agent. Paradoxically, increased prescribing 
rates of dexmedetomidine has evoked interest in optimising the role of clonidine.
6,7
 Of particular 
importance for paediatric use is that clonidine displays age-related changes in pharmacokinetics 
attributable to the maturation of clearance during infancy.
8
 It has a long elimination half-life (16.9 
hours in neonates, 11.4 hours in infants and 7.4 hours in children).
9
 Additionally, intravenous 
formulations of clonidine are currently not marketed in North America although an oral formulation is 
available. Both oral and intravenous formulations are however commercially available in Europe. 
Bioavailability of orally administered clonidine formulations has been estimated to be approximately 
55% in children.
10
 Paediatric-derived information to date, on both α2 agonists, has been scarce with 
limited evidence of efficacy on sedation outcomes.
1,2
  
Evidence to support a particular dosage regimen of clonidine has also been limited. Of the 
RCTs previously performed, one previous study [Duffet et al.]
11
 was a pilot study and not powered for 
efficacy outcomes, and two studies [SLEEPS and CloSed]
12,13
 encountered recruitment difficulties 
prohibiting analysis of pre-planned outcomes. A final study [Hunseler et al.]
14
 reported efficacy as an 
opioid-sparing agent, though this was only observed in one age stratum, that of neonates. It has been 
proposed the isolated signs of efficacy (reduced fentanyl administration) in this RCT was due to 
higher plasma clonidine levels in neonates versus older infants due to the underdeveloped clearance 
in neonates.
9
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Recruitment difficulties within the multisite European CloSed trial suggest evidence from 
RCTs of dosage regimen efficacy might remain elusive for the near future.
13
 A recent comparative 
effectiveness observational study included 692 children in Ireland who received clonidine while 
mechanically ventilated.
15
 While an increased time at the target sedation score was observed, a 
concomitant decrease in opioid and benzodiazepine use was not found. Of note, clonidine 
intravenous bolus dosages in this study were in the range of 1-2 µg/kg six to eight hourly. Continuous 
intravenous infusions were not used in this study. There appears to be a shift; however, within the 
literature, towards higher clonidine dosage regimens than the dosages which are in current clinical 
practice in Ireland.
16
 While the optimal clonidine dosage regimen remains undefined, it is reasonable 
to consider many children may be sub-optimally dosed within the current practice, although this has 
not been formally tested. Population pharmacokinetic parameters for clonidine have previously been 
published
8
, although comparing these is sometimes difficult unless the standardised maturation 
parameters are used.
17
 These parameters provide for formal clonidine dosage simulations to predict 
plasma concentrations achieved by various dosing strategies.  
The aim of this study was first to provide some rationale for a proposed target concentration 
for sedation in PICU, and second to assess whether clonidine dosage regimens used in previous 
clinical studies and in routine practice are likely to achieve this therapeutic concentration. Patient 
demographics of the 692 included children from the recent comparative effectiveness study of 
clonidine in Ireland are used in the simulation replicating a real-life clinical population. This study will 
inform both current off-label clinical practice and provide evidence for dosage regimen design in future 
clonidine RCT attempts. 
 
Methods: 
Method for pharmacodynamic analysis for the proposal of a clonidine target plasma concentration 
 
A comprehensive literature review was undertaken in order to identify pharmacokinetic-
pharmacodynamic (PKPD) studies on clonidine and sedation. The search terms clonidine AND 
pharmacodynamics were used in PUBMED with limits to clinical trials and human subjects. The 
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search was carried out in January 2019. Titles and abstracts were screened to identify studies 
detailing clonidine use alone as a sedative. 
 
Only one PKPD study was identified.
18
 The single study found which used clonidine in the absence of 
other sedative agents was a study by Hall et al.
18
 This study was conducted in healthy adults 
volunteers, who received doses of 0, 1, 2 and 4 µg/kg over 15 min followed by 45 min of continuous 
infusion. Sedation was measured by bispectral index (BIS) which analyse the EEG signal by providing 
a value between 0 and 100 inversely correlated with the level of hypnosis.  
 
For our present study, we extracted data from the study by Hall et al.
18
 Experimental data (BIS scores 
with time under different clonidine dose schemes) from this study were extracted. No PK data were 
reported by Hall et al
18
, and hence we used typical PK parameters from a previous study by Larsson 
et al.
10
 An effect compartment model was then used to estimate the delay between predicted plasma 
concentration and effect. 
 
This effect compartment concentration was then used to derive a sigmoidal Emax model of the BIS 
score with time. As follows: 
 
                           
           
              
 
where BISmax is the maximum BIS score (the baseline), Ce is the effect compartment concentration, 
BIS50 the concentration to decrease BIS score by half, and Hill is the Hill coefficient (shape 
parameter). The target was assumed to be a BIS score of approximately 60-70.
19
 
Method for Dosage Regimen Identification  
Eligible studies were identified from a recent systematic review which included three clonidine RCTs.
1
 
In addition, the ongoing CloSed trial was included.
13
 Dosage regimens used in local clinical practice in 
Ireland were also included.
16
 
Clinical and Pharmacokinetic Parameters used in the PK simulation 
Demographic details from the 692 children who received clonidine while mechanically ventilated in a 
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recent comparative effectiveness observational study were extracted (Table 1)
16
 These children 
represent a 30 month admission period in the PICUs of Our Lady's Children's Hospital, Crumlin, 
Dublin, Ireland, and Children's University Hospital, Temple Street, Dublin. Gestational and postnatal 
age alongside body weight at admission were detailed for each child who received clonidine. 
Clonidine pharmacokinetic data were obtained from the model of Larsson and al.(Table 2).
10
  This 
model used a sigmoidal postmenstrual age function.
17
  
          
   
  
 
    
 
    
    
     
          
    
 
where CL is drug clearance in an individual, CLT  is the typical CL for a 70 kg adult, WT is body 
weight, PMA5 0 is the PMA (usually in weeks) for CL to reach 50% mature, and Hill is the shape 
parameter describing the steepness of the clearance maturation curve.  Volume and inter 
compartmental clearance (Q) were scaled with standard allometric scaling (exponents of 1 for central 
and peripheral volume, 0.75 for Q) centred on 70kg  
Pharmacokinetic model and simulations detail 
Using this model and the dataset including the demographic data of the 692 children, simulations 
were performed with NONMEM (version 7.4) to predict plasma concentrations of clonidine for the 
nominated dosage regimens in 24 hours of treatment. Variable dosage range infusions were 
permitted in two studies. These were the SLEEPS RCT [0-3 µg/kg/hr], and the CloSed RCT [dosage 
for neonates was 1 µg/kg over 15 mins followed by 0.5-1 µg/kg/hr, and the dosage for older children 
was 2 µg/kg over 15 mins followed by 1-2 µg/kg/hr]. For the purposes of the simulation, the mid-way 
point of each infusion range was chosen. For the SLEEPS RCT this was 1.5 µg/kg/hr. For the CloSed 
neonatal dosage this was 0.75 µg/kg/hr and 1.5 µg/kg/hr for older children. The CloSed study also 
permits additional rescue boluses if insufficient sedation is not achieved. These were not included in 
the simulation in this study. Plasma concentration profiles for 24 hours were plotted using R 
(Version 3.4.4) to determine if therapeutic levels are likely to be achieved. Median plasma 
concentrations of clonidine attained by each child at each time point along with 95
th
 percentiles were 
plotted.  
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Results 
Results of the pharmacodynamic analysis for the proposal of a clonidine target plasma concentration 
Pharmacokinetic data were modelled for the four dose levels [0, 1, 2 and 4 µg/kg] given by Hall et al.
18
 
using fixed parameters updated from Larsson et al. (Table 2).
10
 The observed/population predicted 
plasma concentrations versus time are given in Supplementary Figure 1.   
A sigmoid Emax model was then used to describe the pharmacodynamic relationship between 
concentration and BIS score. No improvement in fit was observed with Hill estimated or fixed equal to 
one. The BIS50 was estimated at 5.29 µg/L, the effect compartment equilibration coefficient at 5.74 h
-1
 
and the baseline (BISmax) was estimated at 97.5. Figure 1 shows the experimental data, along with the 
population model predictions of BIS measurements versus time.  
Figure 2 shows that target concentrations of 2, 3 or 4 µg/L correspond to a BIS score of 71, 62 and 56 
respectively 
Results for Target Plasma Clonidine Concentration 
The BIS derived target suggests adequate sedation at concentrations of 3 µg/L, but in most cases 
patients will require analgesia using agents with sedative effects. A study conducted by Arena-Lopez 
et al.
20
 in children showed adequate sedation once steady state has reached an average clonidine 
concentration around 1.4 µg/L. In this study, sedation was measured by COMFORT score after 
administration of clonidine and morphine. Clonidine was administered via the nasogastric tube at 1 
µg/kg followed one hour later by 3 µg/kg every eight hours and, depending on sedation requirements, 
this dose could be adjusted up to 5 µg/kg. In addition, lorazepam bolus doses (50–100 mg/kg) were 
used prior to invasive procedures and to provide appropriate sedation. Current clinical practice 
favours use of clonidine as an adjunct agent alongside an opioid infusion to minimise further opioid 
and benzodiazepine requirements. Hence, based on the results from the Hall study
18
 and taking into 
consideration the adequate sedation obtained in the study by Arenas Lopez et al.
20
, a minimum target 
concentration above 2 µg/L was chosen to evaluate the adequacy of clonidine dosage regimens. This 
target level of 2 µg/L has also been proposed in a study of clonidine PK-PD during paediatric 
extracorporeal membrane oxygenation.
21
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Results of Dosage Regimen Identification 
A summary of the included studies is included in Table 3. Three large-scale clonidine RCTs have 
been attempted to date or are on-going
12-14
, in addition to one pilot RCT
11
. Within these four RCTs, 
one study used a fixed bolus of 5 µg/kg six hourly via the nasogastric route
11
, one study used a fixed 
infusion of 1 µg/kg/hr 
14
, and two studies used a loading bolus followed by a variable infusion rate up 
to 2 µg/kg/hr in the CloSed study
13
 and 3 µg/kg/hr in the SLEEPs study
12
. The final observational 
study reflects local practice in PICUs in Ireland with a bolus dosage of 1-2 µg/kg six to eight hourly. 
Additional studies have described similar intravenous clonidine bolus dosages within the lower range 
of 1- 2.5 µg/kg
8
. For the CloSed study dosages were halved in neonates and a series of additional 
boluses were permitted if insufficient sedation was achieved. All efficacy studies included were based 
on the use of clonidine in combination with an opioid. This is likely due to the need for sufficient 
analgesia alongside the use of sedatives. 
 
Plasma profiles obtained following PK simulation 
The results for the simulated plasma clonidine concentrations for the first 24 hours of treatment are 
shown in Figure 3. The intravenous bolus dosages of 1-2 µg/kg 6-8 hourly studied did not achieve the 
target plasma concentration. The higher nasogastric dosage of Duffett et al. was associated with 
significant time above the target concentration although high variability was observed with this route 
of administration.
11
 The intravenous infusion regimens attained the target levels for many children. 
The study by Hunseler et al. of a fixed dosage of 1 µg/kg/hr without a loading dose was associated 
with a longer time to steady-state concentrations than the other infusion regimens. The SLEEPs study 
regimen of a 3 µg/kg/hr loading dose followed by a variable infusion rate of 0-3 µg/kg/hr achieved the 
highest median plasma concentrations with most patients above the target level after five to ten 
hours.
12
 The CloSed study neonatal regimen achieved below target plasma concentrations while a 
majority of the children older than 28 days achieved target concentrations after twenty hours.
13
 
Discussion 
Uncertainty relating to optimal clonidine dosage may have contributed to inconsistent reports of 
efficacy in previous studies. This simulation study was conducted to evaluate the adequacy of 
previously reported clonidine dosage regimens. Firstly a target plasma clonidine concentration of 
above 2 µg/L was proposed using a combination of a pharmacodynamic analysis of a bispectral index 
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study in healthy adult volunteers
18
 along with empirical data from a paediatric critical care study
20
. 
Updated pharmacokinetic parameters incorporating a maturation function are then presented. A 
literature review showed a range of clonidine dosages from 1 µg/kg boluses every 8 hours up to 
infusion rates of 3 µg/kg/hr had been used in previous studies. Simulation of plasma concentrations 
using the demographics of a large cohort of children who received clonidine highlight many of these 
dosage regimens are unlikely to achieve the target plasma concentration. Clinicians should be mindful 
of clonidine pharmacokinetics when selecting a dosage strategy. In particular, the long half-life of 
clonidine in children delays the achievement of steady-state concentrations. Administration by 
continuous infusion is required to achieve concentrations above a minimum threshold of 2 µg/L at 
steady state. Without a loading dose, concentrations above 2 µg/L are not achieved in the first 24 
hours of treatment for many children. Fixed bolus dosages of clonidine via the intravenous or 
nasogastric route produce relatively low plasma concentrations. • Clonidine titrated infusions with a 
loading dose of 2 µg/kg followed by a continuous infusion of up to 2 µg/kg/hr are recommended in 
haemodynamically stable PICU patients to achieve adequate sedation. Doses should be halved in 
neonates. 
Clonidine dosage regimens and target plasma concentrations have evolved in recent years. 
In 2003, a lower concentration range of 0.3 - 0.8 µg/L was estimated as satisfactory for preoperative 
sedation in children 1 - 11 years.
22
 This was consistent with an earlier study in 1998, which found 
postoperative sedation was unsatisfactory in children of 1 - 9 years at concentrations below 0.3 
µg/L.
23
 Studies in adults report therapeutic analgesia and sedation in the range of 1.5 -2 µg/L.
8
  The 
paediatric study by Arenas-Lopez et al. suggests a similar range is adequate in children. Their study 
of twenty-four mechanically ventilated children who received clonidine and morphine had 82% of 
sedation assessments at the target range and showed a majority of steady-state plasma 
concentrations in the range 0.9 – 2.5 µg/L.
20
 Of note, the largest paediatric RCT of clonidine by 
Hunseler et al. did not report plasma clonidine concentrations.
14
 Efficacy was evaluated in three 
different age strata: [Strata One from 0 days to 28 days, Strata Two from 29 days to 120 days and 
Strata Three from 121 days to 2 years]. A significant reduction in fentanyl co-administration was 
reported only in the neonate cohort of Strata One. Subsequently, plasma clonidine concentration 
profiles for each of the three age strata were predicted
9
 based on the dosage regimen employed and 
literature pharmacokinetic parameters by Potts et al.
8
 Steady-state concentrations were predicted at 
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approximate means of 6 µg/L, 5 µg/L and 3 µg/L respectively for each stratum. Given efficacy was 
observed in the youngest cohort only; this would imply that higher plasma concentrations than 
previously anticipated are required. While the optimal clonidine plasma concentration remains 
undefined, concentrations at least above 2 µg/L are warranted, and concentrations up to a median of 
6 µg/L are attained in mechanically ventilated children. Potts et al. previously proposed a dosage 
regimen for clonidine infusions aimed at maintaining plasma concentration above 0.3 µg/L with a 
median concentration target of 1 µg/L.
8
 A loading dose of 1 µg/kg followed by an infusion of 2 µg/kg/hr 
for 30 minutes, 1 µg/kg/hr for 30 minutes to 1 hour, then 0.5 µg/kg/hr for 1 to 3 hours and 0.3 µg/kg/hr 
thereafter. To our knowledge, this regimen has not been incorporated into subsequent clinical studies. 
The relative complexity of this regimen or a preference to reproduce existing clinical practice in 
research studies may have contributed to this. The variety of dosage regimens of clonidine described 
in the literature reflects a research gap that should be addressed before future efficacy studies are 
attempted. 
When contemplating loading doses and increasing target plasma concentrations of clonidine, 
dose-related adverse effects must be considered. The use of α2 agonists may induce hypotension 
and bradycardia by inhibiting cardiac and vascular sympathetic activities.
1
 An important consideration 
is thus, how well tolerated clonidine infusions are in the general PICU population, especially at higher 
dosages. Fear of cardiovascular instability was attributed as a barrier to recruitment in the SLEEPS 
trial evaluating clonidine versus midazolam.
12
 Recently, a cohort study of 168 critically ill children 
evaluated haemodynamic safety in children who received a clonidine infusion as part of their sedation 
regimen.
24
 The study aimed to determine the prevalence of bradycardia and hypotension in a mixed 
population of PICU patients with high disease severity during a clonidine infusion of up to 2 µg/kg/hr. 
Control patients were not included in the study and clonidine plasma concentrations were not 
measured. Clonidine infusions were administered at a median (IQR) maximal infusion rate of 0.7 (0.3 
- 1.5) for 2 days (1 - 6 days) with most (69%) patients receiving a loading bolus of 1- 2 µg/kg at the 
start of the infusion. Severe bradycardia and systolic hypotension occurred in 40% and more than 
50% of included children, respectively. Younger age was the only significant risk factor for 
bradycardia. Despite these high prevalence rates of bradycardia and hypotension, haemodynamic 
stability did not appear to be compromised. Severe bradycardia was unrelated to hypotension, and 
vasoactive drug use decreased in parallel with increasing clonidine infusion rates. Compensatory 
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mechanisms such as increased stroke volume with decreased heart rate and reduced afterload from 
decreased blood pressure are hypothesised to explain this maintenance of stability. Good 
haemodynamic tolerance was also reported in three previous studies of clonidine infusions in children 
under one year after heart surgery
5,7,25
 and a study of clonidine 3 µg/kg nasogastric boluses in 
children under two with respiratory failure
20
. These findings suggest, unless patients are 
haemodynamically unstable, clonidine loading doses and infusions up to 2 µg/kg/hr are tolerated in 
the general PICU population. The results of the simulations of this study support the dosage regimens 
of the SLEEPs study [3 µg/kg loading dose followed by a continuous titrated infusion of 0-3 µg/kg/hr] 
and CloSed study for children older than a month [2 µg/kg loading dose followed by a continuous 
titrated infusion 1-2 µg/kg/hr]. Of note, in this study, the continuous infusion was fixed at the midway 
point of the infusion range and not titrated according to clinical response. Furthermore, the 
additionally permitted rescue boluses for insufficient sedation at the start of the CloSed regimen were 
not included in the simulation. Combining these predicted concentrations with the observed 
haemodynamic safety data of the study by Kleiber et al.
24
 supports an initial loading dose of 2 µg/kg 
(with intermittent rescue doses if insufficient sedation achieved) followed by a continuous infusion of 
0-2 µg/kg/hr titrated according to sedation scores. Doses should be halved in neonates. 
Despite being an older drug in widespread clinical use, there is limited knowledge on optimal 
dosage regimens. This is the first study in the literature to simulate the various dosage regimens 
employed in previous randomised controlled trials alongside in clinical practice. A strength of this 
study is the inclusion of the demographics of children who received clonidine for the indication of 
sedation. The large population of almost seven hundred children should increase the generalisability 
of the study findings. A further strength of the study is the updated pharmacokinetic parameters 
incorporating maturation function, and this adds to the literature for clonidine in children. A potential 
limitation of the study is uncertainty of the target plasma concentration for clonidine to provide 
sedation alongside opioids in mechanically ventilated children. The target proposed in this study is 
partly informed by a study using the BIS in adults. The extrapolation of BIS data to paediatrics where 
it is less well validated is a limitation of this study. The BIS was developed from adult EEG data and 
paediatric EEGs may differ markedly. Despite these differences, studies suggest that the performance 
of BIS in children older than six months is similar to that in adults.
26 27
 BIS has been found to correlate 
with sedation measured with the Ramsay sedation scale
28
 , the University of Michigan Sedation 
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Scale
29
] and the COMFORT Behaviour scale
30
. BIS is however less useful at identifying 
undersedation than it is oversedation and evidence is limited in younger infants, particularly in 
neonates. with low BIS values seen even with only light sedation
31
 . Given this limitation, we also 
incorporated paediatric efficacy data from a study of oral clonidine in infants. This study cohort 
included neonates and supported clonidine concentrations averaging 1.4 µg/L.  The proposed target 
of above 2 µg/L represents a compromise between the available data.  Further pharmacokinetic-
pharmacodynamic data from cohorts of adequately sedated children receiving clonidine (such as that 
which should arise from the data available from the CloSed study) may aid clarification of target 
plasma concentrations and further confirm an optimal dosage regimen. Trials of efficacy have 
encountered recruitment difficulties and have employed heterogeneous dosing strategies. An 
evidence-based dosing regimen is a pre-requisite for further trial attempts. Even outside of research 
studies, clonidine dosage in practice should reflect an evidence-based foundation. 
Conclusions: 
Off-label use of older drugs in paediatrics, such as clonidine, has meant a bypassing of traditional 
dose-determining clinical studies during drug development. This has led to clinicians employing 
heterogeneous dosage regimens without a supporting evidence-base. This is likely to contribute to 
the lack of efficacy data available from clinical studies to support the use of clonidine as a sedative in 
critically ill children. Simulations of clonidine plasma concentrations based on known population 
pharmacokinetic parameters suggest a loading dose followed by a continuous infusion is required to 
achieve adequate steady-state concentrations early in treatment. A limitation of this method, however, 
is the lack of clarity of the therapeutic clonidine plasma concentration. Further pharmacokinetic-
pharmacodynamic studies will further aid in the determination of the optimal clonidine dosage 
regimen.  
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Table 1: Characteristics of children included in the simulation  
Characteristic   N % 
Number of Patients   692   
      
Gender Male 387 56 
  Female 305 44 
        
Corrected Age Category (at admission) Neonate 234 34 
  1 month - 6 months 242 35 
  6 months - 12 months 76 11 
  12 months - 3 years 57 8 
  > 3 years 83 12 
        
Weight (at admission) <5kg 325 47 
  5kg-10kg 246 36 
  10kg -20kg 80 12 
  >20kg 41 6 
        
Reason for admission  Post-cardiac surgery 346 50 
  Post non-cardiac surgery 44 6 
  Cardiac Disorder (non-
surgical) 
118 17 
  Respiratory Disorder  77 11 
  Gastrointestinal Disorder 35 5 
  Sepsis 25 4 
  Congenital Diaphragmatic 
Hernia 
18 3 
  Seizure 3 0 
  Other 26 4 
        
Baseline Paediatric Logistic Organ Dysfunction 
(PELOD) score 
Mean (SD) 
  6.4 (2.1)   
Paediatric Index of Mortality (PIM2r) score 
Mean (SD) 
  0.04 (0.06)   
Neurodevelopmental Disorder N (%)   163 24 
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Table 2: Pharmacokinetic Parameters derived after updating the model of data by Larsson et 
al.  
  Parameter Estimate %BSV 
Clstd (l h
-1
 70kg 
-1
) 17.9 30.3 
V1std (l 70 kg
-1
) 81.2 71.5 
Qstd (l h
-1
 70 kg
-1
) 121 44.3 
V2std (l 70 kg
-1
) 113 33.9 
Tabs (h) 0.454 85.1 
Tlag 0.148 91.2 
PMA50 (weeks) 61.6  
Hill 2.42  
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Table 3: Characteristics of studies from which clonidine dosage information was derived  
Study Route of administration Regimen Number of patients Patient characteristics 
Hayden at al.
15
 Intravenous 1-2 µg/kg 6- 8 hourly 692 Mechanically ventilated children 0 days -18 
years 
Duffett et al.
11
 Nasogastric 5 µg/kg 6 hourly 50 Mechanically ventilated children 30 days - 18 
years 
Hunseler at al.
14
 Intravenous 1 µg/kg/hr 219 Mechanically ventilated children under 2 years 
Wolf at al.
12
 
(SLEEPS) 
Intravenous 3 µg/kg loading over 1 hour followed by 0-3 
µg/kg/hr titrated infusion 
120 Mechanically ventilated children 30 days - 15 
years 
Neubert at al.
13 
CloSed) 
Intravenous 2 µg/kg loading over 15 mins followed by 1-2 
µg/kg/hr titrated infusion 
200 planned Mechanically ventilated children 28 days - 18 
years 
Neubert at al.
13
 
(CloSed) 
Intravenous 1 µg/kg loading over 15 mins followed by 
0.5-1 µg/kg/hr titrated infusion 
100 planned Mechanically ventilated children 0 days - 28 
days 
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Supplementary Figure 1: Plot of the observed and population predicted plasma concentrations versus 
time for the four dosage levels given by Hall et al.[0, 1, 2 and 4 µg/kg over 15 min followed by 45 min 
of continuous infusion].The circles/black line is the observed data, and the dotted line is the model 
prediction. 
Figure 1:  Plot of the observed and population predicted BIS score versus time for the 4 dose levels 
given by Hall et al. [0, 1, 2 and 4 µg/kg over 15 min followed by 45 min of continuous infusion]. Circles 
are observed BIS data from Hall et al. and the dashed line is the model prediction 
Figure 2: The Model predicted change in BIS index with clonidine concentration 
Figure 3: Simulated plasma clonidine concentrations. A= 1µg/kg/8h IV bolus, B= 1µg/kg/6h IV bolus, 
C= 2µg/kg/8h IV bolus, D= 2µg/kg/6h IV bolus, E = 5µg/kg/6h NG bolus (Duffett at al), F= 3µg/kg/h 
loading then 1.5µg/kg/h IV infusion (Wolf et al/SLEEPS), G= 1µg/kg/h IV infusion (Hunseler et al),    
H= 1µg/kg/h then 0.75µg/kg/h IV infusion (Neubert et al/CloSed neonates), I=  2µg/kg/h then 
1.5µg/kg/h IV infusion (Neubert et al/CloSed > age 28 days). The dotted line represents the minimum 
target concentration. The black line is the predicted median concentration, and the dashed line 
represents the 95% Confidence Interval.  
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